Diabetic retinopathy environment-wide association study (EWAS) in NHANES 2005-8.

- 3 Kevin Blighe, Ph.D.¹, Sarega Gurudas, MSC.¹, Ying Lee, Ph.D.¹, Sobha Sivaprasad,
- 4 FRCOphth. 1,2,*

1

2

5

10

15

- ¹University College London, Institute of Ophthalmology, London, EC1V 9EL, United
- 7 Kingdom.
- 8 ²National Institute for Health Research, Moorfields Biomedical Research Centre, London,
- 9 United Kingdom.
- 11 *corresponding author:
- 12 Professor Sobha Sivaprasad
- 13 sobha.sivaprasad@nhs.net
- 14 +44 (0)20 7566 2039

16

17

18

19

23

25

26

27

29

33

34

35

36

37

38

39

40

SUMMARY Background: Several circulating biomarkers are reported to be associated with diabetic retinopathy (DR). However, their relative contributions to DR compared to known risk factors, such as hyperglycemia, hypertension, and hyperlipidemia, remain unclear. In this 20 data driven study, we used novel models to evaluate the associations of over 400 laboratory 21 parameters with DR. 22 Methods: We performed an environment-wide association study (EWAS) of laboratory parameters available in National Health and Nutrition Examination Survey (NHANES) 24 2007-8 in individuals with diabetes with DR as the outcome (test set). We employed independent variable ('feature') selection approaches, including parallelized univariate regression modeling, Principal Component Analysis (PCA), penalized regression, and RandomForestTM. These models were replicated in NHANES 2005-6 (replication set). 28 Findings: The test and replication set consisted of 1025 and 637 individuals with available DR status and laboratory data respectively. Glycohemoglobin (HbA1c) was the strongest risk 30 factor for DR. Our PCA-based approach produced a model that incorporated 18 principal 31 components (PCs) that had AUC 0.796 (95% CI 0.761-0.832), while penalized regression 32 identified a 9-feature model with 7851% accuracy and AUC 0.74 (95% CI 0.72-0.77). RandomForestTM identified a 31-feature model with 78.4% accuracy and AUC 0.71 (95% CI 0.65-0.77). On grouping the selected variables in our RandomForestTM, hyperglycemia alone achieved AUC 0.72 (95% CI 0.68-0.76). The AUC increased to 0.84 (95% CI 0.78-0.9) when the model also included hypertension, hypercholesterolemia, hematocrit, renal and liver function tests. **Interpretation:** All models showed that the contributions of established risk factors of DR especially hyperglycemia outweigh other laboratory parameters available in NHANES.

RESEARCH IN CONTEXT

41

45 46

47

48

49

50

51

53

54

55

56

58

61

65

- 42 What is already known about this subject?
- There are >500 publications that report associations of candidate circulating biomarkers with diabetic retinopathy (DR).
 - Although hyperglycemia, hypertension, and hyperlipidemia are established risk factors, they do not always explain the variance of this complication in people with diabetes; DR also shares risk factors with other diabetes complications including markers of renal and cardiovascular disease.
 - 'Holistic' studies that quantify risk across all of these parameters combined are lacking.
- What is the key question?
 - It is unclear whether risk models for DR may be improved by adding some of these reported biomarkers there is an unmet need to systematically evaluate as many circulating biomarkers as possible to help rank their associations with DR.
- What are the new findings?
 - We show that hyperglycemia is the strongest risk factor across all models.
- We stratified the rest of the highest ranked parameters into groups related to diabetes control, renal and liver function, and hematocrit changes.
- How might this impact on clinical practice in the foreseeable future?
- The importance of focusing on parameters beyond hyperglycemia control to reduce risk of progression from diabetes to DR is emphasized.

Diabetes represents the most common cause of microvascular changes in the retina. The

INTRODUCTION

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

initial retinal lesions of diabetic retinopathy (DR) are microaneurysms but they can occur in eyes with and without diabetes (1-3). With increasing duration of diabetes, other lesions develop and co-exist in the retina such as retinal hemorrhages, exudates, intraretinal microvascular abnormalities and neovascularization of the retina or optic disc. Based on the presence of individual lesions or a constellation of them, DR severity level is graded from mild, moderate and severe non-proliferative diabetic retinopathy (NPDR) to proliferative diabetic retinopathy (PDR) (4, 5). Diabetic macular edema (DME) can occur in any stage of DR (5). In population-based studies, approximately a third of people with diabetes have DR (6, 7). The established systemic risk factors for DR are suboptimal control of hyperglycemia, hypertension and hyperlipidemia (8, 9). Hypertension can also cause some of these retinal lesions independent of diabetes (10). There are several laboratory parameters that have been shown to be abnormal in people with DR such as hyperuricemia (11), low vitamin D levels (12), low thyroxine levels (13), anemia (14), oxidative stress and inflammatory markers (15). In addition, DR is also associated with markers of diabetic kidney disease including microalbuminuria and serum creatinine (16, 17) and cardiovascular disease markers such as raised C-reactive protein (CRP) (18). Most of these associations and risks of DR are reported based on analysis of candidate laboratorybased serum or urinary markers. In addition to these risk factors, there are several other non-modifiable and modifiable risk factors that have been attributed to the development and progression of DR. Some of these include age of onset of diabetes, duration of diabetes, male sex, and ethnicity (19-21).There is an unmet need to rank these reported retinal, systemic and laboratory risk factors to understand their relative contributions or associations with DR in people with diabetes. The National Health and Nutrition Examination Survey (NHANES https://wwwn.cdc.gov/Nchs/Nhanes/) was initiated in the 1960s in order to examine the health and nutritional status of US citizens and has been surveying the population up to the present time. Since 1999, it has examined ~5000 citizens per year and includes various topics, including cardiovascular disease, diabetes, environmental exposures,

97 eye diseases, hearing loss, infectious diseases, kidney disease, nutrition, etc. The data

also contains several laboratory markers including environmental toxins, allergens,

99 pollutants.

98

102

103

104

105

106

107

109

119

120

123

124

125

126

100 In this study, we used an environment wide association study (EWAS) methodology

101 (22-25) on NHANES 2007-8 to evaluate the rank order of systemic and laboratory

risks of DR among individuals identified as having diabetes to evaluate their relative

associations with DR. Our findings are then replicated in NHANES 2005/6. Our

objective is not to only use previously reported risk factors but also provide new

research avenues from this data driven agnostic modelling study.

METHODS

Study data preparation

108 We used National Health and Nutrition Examination Survey (NHANES) 2007-8 as our

primary cohort and 2005-6 as a replication cohort. Both datasets were prepared in the

same fashion, however, for ease of interpretation, the following methods describe

111 2007-8. Specifically, three main categories of data were used: examination data

112 (Ophthalmology - Retinal Imaging data; OPXRET E), demographics data (DEMO E),

and laboratory data (Figure 1 footnote). The main outcome of interest in the

114 examination data was 4 levels retinopathy severity, worse eye (OPDURL4) – this

variable was recoded as binary with levels: no retinopathy; retinopathy (including mild

NPR, moderate/severe NPR, and proliferative). All datasets were downloaded as SAS

117 XPORT (xpt) format and read into R (v4.0.2) via the *Hmisc* package.

118 Individuals with a missing value in the main outcome variable were removed before

aligning the examination, demographics, and laboratory data via each individual's

respondent sequence number (SEQN). This dataset was then further filtered for only

those individuals who had diabetes (**Figure 1**). Variables were removed from the data

that had 0 variance (i.e. constant values) (Supplementary Table 1). Prior to any

analysis, in addition, any variable that contained a single value occupying > 90% of

total values was removed, as were variables that had > 90% missingness. Further

specific filtering and encoding was then applied per dataset. [A] Examination data:

variables that were different encodings of the main outcome were removed; variables

that related to the status of the examination appointment were removed; OPDUHMA was removed, as it is a combination of 2 other variables that were retained (OPDUMA and OPDUHEM); variables related to glaucoma, for which there is already a single variable, were removed; variables related to the left or right eye where there was already a variable for 'worse' eye were removed; values encoded as missing were recoded as NA; and all other remaining variables were encoded as binary, with 0 representing the absence of the condition, and 1 representing any recorded presence (at any level) of the condition. [B] Demographic data: variables associated with interpreters and the language of the interview were removed; variables that were duplicates or different encoding of each were removed. [C] Laboratory data: categorical variables were removed and only continuous retained; duplicate variables related to the oral glucose tolerance test (OGTT E) were removed; variables related to time since domestic activities ('pump gas', 'shower', etc.) were removed; variables that were duplicates or different encodings of each were removed; variables measured on the imperial system of weights and measures were removed if they had a corresponding variable in SI units. We focused only on continuous laboratory variables for the following reasons: 1, in NHANES, the majority of categorical variables are derived from the continuous variables; 2, our PCA-based approach can only work on continuous variables; 3, for RandomForestTM, having continuous variables increases the number of splitting points in the data, and metrics of importance such as Gini are known to exhibit less bias on such data (26).

Diabetes status

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

156

- To define the diabetes status for each individual, questionnaire data (DIQ E) was used
- in addition to variables already included in the laboratory data. Diabetes status was
- then defined as an individual satisfying any of the following: Self-reported diabetes
- 152 (DIQ010); on anti-diabetes drugs (DIQ070); taking insulin (DIQ050); fasting blood sugar
- 153 (FBS) \geq 6.1 (110mg/dl) (LBDGLUSI); random blood sugar (RBS) \geq 11.1 (200mg/dl)
- 154 (LBDSGLSI); oral glucose tolerance test (OGTT) ≥ 200mg/dl (LBDGLTSI);
- 155 Glycohemoglobin (HbA1c) \geq 6.5% (LBXGH).

Covariates

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

Age, ethnicity, and diabetes duration were used as covariates. Diabetes duration was calculated as age at screening minus the age at which the individual was first informed that he/she had diabetes. Statistical analysis Prior to statistical analysis, continuous laboratory variables were logged (log_e) and then transformed into z-scores to ensure that these were on the same scale. In regression analysis, the complex sampling design of the NHANES dataset was accounted for through use of survey sampling weights via the survey package in R / CRAN. To do this, the following value-pairs were used with the svydesign function: (id, SDMVPSU; strata, SDMVSTRA; weights, WTMEC2YR; nest, TRUE). Univariate analysis was performed on all candidate predictors using a survey-weighted compute-parallelized logistic regression model via the R / Bioconductor package RegParallel, adjusting for age, ethnicity, and duration of diabetes separately. The Benjamini-Hochberg (27) procedure was used to control the type I error false discovery rate (FDR). A customized Manhattan plot was generated using ggplot2, while pairwise scatter and correlation plots were generated via a customized pairs plot. Finally, a heatmap was generated via the R / Bioconductor package ComplexHeatmap. As our study is also hypothesis-generating, multivariate approaches based on principal component analysis (PCA), penalized regression, and the RandomForestTM classification algorithm were additionally used. Variables were pre-filtered and prepared as per univariate testing. Principal component analysis was performed via the R / Bioconductor package *PCAtools*. After conducting PCA, each eigenvector was then independently regressed against retinopathy outcome via binary logistic regression and those that passed p≤0.05 were used to construct a multivariable model that was further tested in ROC analysis via the pROC package in R. Separately, as model complexity and multi-collinearity can arise from a large number of predictors, elastic net regularization (penalized regression with L1 and L2 penalties of the Lasso and Ridge methods) was used to reduce the number of predictor variables using glmnet in R / CRAN. To fit the model, 100x cross-validation was used and alpha (α) set to 0.5. The final chosen variables were those whose coefficients were not

shrunk to zero - these were plot as violin plots with scatter overlays to show

188 differences between non-DR and DR via ggplot2. To determine accuracy, model 189 predictions were made on the data using the lambda (λ) one-standard-error rule using 190 the *predict* function from the *stats* package in R. 191 Finally, the RandomForestTM (RF) model was fitted via the randomForest R / CRAN 192 package. For this, the dataset was divided randomly into 50% training and 50% 193 validation. Prior to model fitting, the initial model was tuned using functionality 194 provided by the *caret* package in R / CRAN, as follows: 1), a 10x cross-validation 195 control function was defined via trainControl function; 2) the best value for 'mtry', 196 i.e., the ideal number of variables to randomly sample, was determined using the train 197 function across a search / tuning grid ranging between 1-40 and with Kappa as the 198 metric; and 3) using the selected value of 'mtry', the ideal number of trees, 'ntrees', 199 was determined also via the train function with selection metric based on Kappa. After 200 the initial model was fit, variables with mean decrease in accuracy ≤ 1% were excluded 201 and the model re-fit. This was then repeated in a recursive fashion until all variables 202 with negative mean decrease accuracy were removed from the model. 203

Final risk models

204

205206

207

208

209

210

211212

215216

187

Variables selected from RandomForestTM were grouped based on similarity of function or clinical use. Each group was then used to create independent univariate or multivariable binary logistic regression models with DR as the end-point. A single Wald test p-value was derived for each model using *wald.test* from the *aod* package. ROC analysis was performed using *pROC*. McFadden's and Nagelkerke's pseudo-R² were derived via the *pscl* and *rms* packages, respectively.

Role of the funding source

- 213 The funders had no role in study design, data collection, data analysis, data interpretation,
- writing, editing the report, or the decision to submit for publication.

RESULTS

217 **Study cohort**

- 218 In NHANES 2007-8, retinal imaging data is available for 3863 individuals, demographics
- data is available for 10149 individuals, and laboratory data is available for between 394 and

9307 individuals, depending on the individual laboratory dataset in NHANES (see Figure 1

footnote). After aligning all data and filtering for those who had diabetes by our

classification, 1025 individuals remained in our dataset. The selection process is illustrated in

Figure 1, while **Table 1** provides an overview of the demographics of these individuals.

- For our replication cohort, NHANES 2005-6, we prepared laboratory data following the same
- 226 filter criteria as NHANES 2007-8 and produced a final dataset of 2459 individuals, among
- which 637 (with retinopathy, 176; no retinopathy, 461) had diabetes.

Retinal lesions of diabetic retinopathy

- To help validate our methodology and cohort selection, we aimed to determine retinal lesions
- that define DR. To this end, we identified 9 retinal lesions in NHANES 2007-8 that were
- 232 statistically significantly associated with DR and survived to p-value adjustment for false
- discovery (**Table 2**). The top lesions were retinal microaneurysms (p≤0.0001), followed by
- 234 retinal hard exudates (typically due to lipoprotein deposition in the retina and may be
- associated with macular edema) (p≤0.0001). Other key lesions at p≤0.0001 were retinal soft
- exudate (now termed cotton wool spots), retinal blot hemorrhages, intraretinal microvascular
- abnormalities (IRMA), and macular edema. In NHANES, retinal microaneurysms and retinal
- blot hemorrhages are encoded to be mutually exclusive, i.e., an individual is recorded as
- having retinal microaneurysms only when not accompanied with retinal blot hemorrhages,
- and vice-versa (**Table 2**).

221

222

223

224225

228229

241242

Univariate logistic regression analysis

- In total, 6 variables reached statistical significance in the unadjusted univariate analysis, 11
- after adjustment for age, 2 after adjustment for ethnicity, and 7 for diabetes duration
- 245 (Supplementary Figure 1; Table 3). Glycohemoglobin (HbA1c) was the only variable that
- was statistically significant in both the unadjusted and adjusted analyses. Other risk variables
- of note that reached statistical significance in the unadjusted analysis included serum glucose
- 248 (mmol/L) (i.e., RBS), osmolality (mmol/Kg), urinary albumin (mg/L), and fasting glucose
- 249 (mmol/L) (i.e., FBS). The only protective variable, i.e., negatively associated, was
- 250 hemoglobin (g/dL). These variables indicate suboptimal diabetes control, abnormal kidney
- 251 function and presence of anemia as risk factors for DR. There was evidence of co-correlation
- among these statistically significant variables from the unadjusted analysis (**Supplementary**
- 253 **Figure 2**).

Interestingly, after adjustment for diabetes duration, the following variables reached statistical significance: HbA1c (%), osmolality (mmol/Kg), urinary iodine (μ g/L), urinary cobalt (μ g/L), urinary triclosan (ng/mL), urinary creatinine (μ mol/L), and urinary barium (μ g/L).

Principal component analysis

Unsupervised PCA using all laboratory variables revealed that 59 PCs could account for 80% or more variation in the dataset. Eighteen PCs were statistically significantly associated with DR at p≤0.05 via independent binomial regression models testing each PC (**Supplementary Table 2**). The top variables responsible for variation along these PCs included measures of blood glucose (HbA1c, random blood glucose and fasting blood glucose), kidney function markers (urinary albumin, blood urea nitrogen [BUN]), hematological markers (hematocrit, hemoglobin, red blood cell distribution width), inflammatory markers (CRP), white blood cell count, urinary nitrates, segmented neutrophil count), and toxic elements (urinary beryllium and cotinine) among others − these PCs were also statistically significantly correlated to microaneurysms, the previously-identified top retinal lesion, and the covariates used during univariate testing (**Supplementary Figure 3**). Through ROC analysis, these 18 PCs achieved AUC 0.796 (95% CI: 0.761-0.832).

Penalized regression model

We fitted an unbiased elastic-net penalized regression model to the laboratory variables and cross-validated it 100x. The model selected 9 variables whose coefficients were not shrunk to zero: urinary albumin, BUN, urinary cobalt, CRP, HbA1c, blood osmolality, serum potassium, systolic blood pressure, and urinary nitrate (**Figure 2**). Of note, these measurements mainly represent diabetes and blood pressure control and kidney function. This model had an accuracy of 78.51% and AUC 0.74 (95% CI: 0.72-0.77) when predicted on the same dataset on which the model was produced.

RandomForestTM classification model

From our RandomForest™ model, HbA1c was the single best predictor of DR (mean decrease accuracy, 31.94%; Gini, 21.75) (**Table 4**). However, other notable variables of appreciable accuracy were markers of diabetes control (FBS, RBS) inflammation (CRP), kidney function (potassium, BUN, creatinine and urinary albumin), hematological markers

(hematocrit), systolic blood pressure, among others. The overall accuracy of the model on the validation cohort was 78.4% and AUC 0.71 (95% CI: 0.65-0.77).

Replication cohort

287

288

289290

299 300

- 291 In the NHANES 2005-6 replication cohort, we performed penalized regression and
- 292 RandomForest™ in the same way as per the 2007-8 cohort. Our penalized regression model
- identified urinary albumin (mg/L), cockroach IgE antibody (kU/L), HbA1c (%), hemoglobin
- 294 (g/dL), and urinary nitrate (ng/mL), with a model accuracy of 73 16% and AUC 0.76 (95%
- 295 CI: 0.73-0.78). RandomForestTM identified HbA1c (%) as the variable contributing most to
- accuracy (mean decrease 16.96%), with many other variables contributing appreciable
- accuracy to the overall model (Supplementary Table 3) the overall model accuracy was
- 298 72 98% and AUC 0 68 (95% CI: 0 61-0 75).

Final clinical risk models

- 301 The 31 features identified by RandomForest™ (Table 4) were grouped into different
- categories of blood tests according to diabetes status, hematocrit values, blood pressure (BP),
- 303 immune markers, renal function, sterols, toxins and metals, and liver function. When
- 304 modeled against DR outcome, each group varied in performance; diabetes tests alone
- achieved AUC 072 (95% CI: 068-076). A final clinical risk model comprising diabetes tests,
- 306 BP, renal and liver function tests, hematocrit values, circulating sterols and immune markers
- 307 achieved AUC 084 (95% CI: 078-09) (p=000013) (Nagelkerke R² 036) (**Table 5**; **Figure**
- 308 **3**).

309310311

320

DISCUSSION

- 312 This EWAS of NHANES 2007-8 data with DR outcomes in individuals with diabetes
- included an unbiased feature selection approach based on a rudimentary univariate regression
- enabled for compute parallelization, PCA, penalized regression, and RandomForestTM of a
- large number of laboratory parameters. In contrast, epidemiological studies are typically
- 316 conducted based on pre-conceived hypotheses and involve a single or just a few variables.
- 317 These methods can be scaled to datasets of any size and therefore provide ways of working
- 318 with large clinical and epidemiological datasets for the purpose of searching for novel
- 319 hypotheses that could then lead to further focused investigations.

321

322

323

324

325

326327

328

329

330

331

332

333

334

335

336

337338

339

340 341

342

343

344

345

346

347

348

349

350

351

352

353

354

In our rudimentary approach, which is ultimately running many univariate models in a parallelized fashion, HbA1c was the only variable to reach statistical significance after adjusted for age, ethnicity, and diabetes duration. The relationship between HbA1c and DR has been explored extensively and was selected as the strongest risk factor in every approach we undertook, with a mean decrease accuracy of 31 94% via RandomForestTM. Our penalized regression and RandomForestTM algorithms also identified an association between elevated systolic blood pressure —but not diastolic— and DR (mean decrease accuracy, 1.9%), again confirming literature (10, 28-30). Further risk variables identified by both penalized regression and RandomForestTM were renal function tests including BUN, urinary albumin, potassium, osmolality, and urinary nitrate. These confirm the strong association of DR with markers of impaired kidney function. Other known risk factors that contributed higher up in the ranking order include hematocrit (%) and cholesterol. Although HbA1c has the strongest association with DR, our study highlight how the addition of other clinical parameters, e.g., from renal and liver function and hematocrit can increase the sensitivity and specificity of predicting DR outcome, with our final clinical risk model achieving AUC 0.83 (95% CI: 0.77-0.89) (p=0.00012) (Nagelkerke R² 0.33), higher than any traditional diabetes control parameter in isolation or in combination. The EWAS methodology and our RandomForestTM approach of non-targeted recursive feature also indicates a small contribution from toxins and metals, including 3hydroxyphenanthrene, 9-hydroxyfluorene, phthalates, blood o-Xylene, and blood nitromethane. Therefore, retina may be a target tissue for environmental contamination. Some of the associations provide directions to future mechanistic research in DR. For example, we found that retinal microaneurysms (FDR-adjusted p≤0.0001), the most statistically significant retinal lesions in individuals with DR, is already correlated with some of the variables such as HbA1c, CRP, BUN, beryllium, and hematocrit, suggesting early effects. In contrast, increased urinary cobalt, triclosan and barium became significant only when adjusted for duration of diabetes. Most of these parameters are also linked to risk of allergies and lung disease, an association that has not been previously explored systematically. As this is a cross-sectional study, a cause-effect relation cannot be established. Moreover, we are unable to rule out any confounding effects of any unmeasured factors. On the other hand, the main strength of the study is the use of the well characterised NHANES cohort in whom standardised protocols were used to measure laboratory parameters. We are not aware of any

355

356

357

358 359

360

361

362

363

364

365

366

367

368

369 370

371

372

373374

375

376377

378

379

380

381 382

383

384

385

386

387 388 other association studies in DR where over 400 laboratory parameters were analysed simultaneously to develop multiple models. As the top variables of all four data driven agnostic models were similar, we also believe our findings are generalisable. CONCLUSION We confirm that DR is a complex disease and that the already established risk factors contribute significantly to the risk models of DR, with HbA1c being the strongest risk factor. Although our model provides an accuracy of approximately 80%, it also provides mechanistic insights into future research on DR including interrogating the interaction of low-ranking risk factors with more established factors in the models and highlights need to explore epigenetic screens to gauge better how risk factors influence gene expression. Most importantly, the study reinforces the need to control known risk factors of DR, especially hyperglycemia. ACKNOWLEDGEMENTS We thank the many thousands of NHANES study participants who, over the course of decades, have provided valuable information for epidemiological studies. **FUNDING** This work was funded by Global Challenges Research Fund and UK Research and Innovation through the Medical Research Council grant number MR/P027881/1. The research was supported] by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. **AUTHOR CONTRIBUTIONS** KB, SG and SS conceived and designed the study. KB, SG and YL analysed the data. KB is the study data guarantor. All authors interpreted the results and reviewed the manuscript. KB had full access to all of the data and takes responsibility for the integrity of the data and the accuracy of data analysis. All authors read and approved the final manuscript.

TABLES

Table 1. Demographic overview of study cohort.

| Characteristics mean (±SD) n (%) | | Diabetes with no diabetic retinopathy (n=787) | Diabetic retinopathy (n=238) | p-value | β-coefficient | OR (95% CI) |
|--|---|--|------------------------------|----------|---------------|------------------|
| Age | - | 62.39 (±11.02) | 63.53 (±10.54) | 0.16 | 0.01 | 1.00 (1.00-1.02) |
| Sex | Male | 420 (53.37) | 126 (52.94) | - | i | - |
| | Female | 367 (46.63) | 112 (47.06) | 0.91 | 0.02 | 1.02 (0.76-1.36) |
| Ethnicity | Non-hispanic white | 369 (46.88) | 91 (38.23) | - | - | - |
| | Non-hispanic black | 166 (21.09) | 74 (31.09) | 0.0012 | 0.59 | 1.81 (1.27-2.58) |
| | Mexican-American | 138 (17.54) | 41 (17.23) | 0.38 | 0.19 | 1.21 (0.79-1.83) |
| | Other Hispanic | 89 (11.31) | 28 (11.77) | 0.32 | 0.24 | 1.28 (0.79-2.07) |
| | Other race - including multi-racial | 25 (3.18) | 4 (1.68) | 0.43 | -0.43 | 0.65 (0.22-1.91) |
| Education | Less than 9 th grade | 148 (18.8) | 54 (22.69) | - | ı | - |
| | 9-11 th grade [±] | 148 (18.8) | 51 (21.43) | 0.8 | -0.06 | 0.94 (0.61-1.47) |
| | High school graduate / GED or equivalent | 199 (25.29) | 56 (23.53) | 0.24 | -0.26 | 0.77 (0.5-1.19) |
| | Some college or AA degree | 172 (21.86) | 55 (23.11) | 0.55 | -0.13 | 0.88 (0.57-1.35) |
| | College graduate or above | 120 (15.25) | 22 (9.24) | 0.014 | -0.69 | 0.5 0.29-0.87) |
| Marital status | Married | 464 (58.96) | 133 (55.88) | - | - | - |
| | Widowed | 119 (15.12) | 36 (15.13) | 0.8 | 0.05 | 1.06 (0.69-1.61) |
| | Divorced | 90 (11.44) | 37 (15.55) | 0.099 | 0.36 | 1.43 (0.94-2.2) |
| | Separated | 32 (4.07) | 7 (2.94) | 0.53 | -0.27 | 0.76 (0.33-1.77) |
| | Never married | 53 (6.73) | 18 (7.56) | 0.56 | 0.17 | 1.19 (0.67-2.09) |
| | Living with partner | 29 (3.68) | 7 (2.94) | 0.69 | -0.17 | 0.84 (0.36-1.97) |
| Family income | \$0-\$4999 | 11 (1.4) | 3 (1.26) | - | - | - |
| | \$5000-\$9999 | 47 (5.97) | 12 (5.04) | 0.93 | -0.07 | 0.94 (0.23-3.89) |
| | \$10000-\$14999 | 82 (10.42) | 22 (9.25) | 0.98 | -0.02 | 0.98 (0.25-3.84) |
| | \$15000-\$19999 | 68 (8.64) | 22 (9.25) | 0.81 | 0.17 | 1.19 (0.30-4.64) |
| | \$20000-\$24999 | 69 (8.77) | 25 (10.5) | 0.68 | 0.28 | 1.33 (0.34-5.16) |
| | \$25000-\$34999 | 103 (13.09) | 42 (17.65) | 0.55 | 0.40 | 1.50 (0.40-5.63) |
| | \$35000-\$44999 | 68 (8.64) | 23 (9.66) | 0.76 | 0.22 | 1.24 (0.32-4.84) |
| | \$45000-\$54999 | 55 (6.99) | 12 (5.04) | 0.76 | -0.22 | 0.80 (0.19-3.31) |
| | \$55000-\$64999 | 41 (5.21) | 15 (6.3) | 0.68 | 0.29 | 1.34 (0.33-5.48) |
| | \$65000-\$74999 | 36 (4.57) | 6 (2.52) | 0.53 | -0.49 | 0.61 (0.13-2.86) |
| | \$75000-\$99999 | 44 (5.59) | 12 (5.04) | 1.00 | 0.00 | 1.00 (0.24-4.17) |
| | ≥\$100000 | 88 (11.18) | 17 (7.14) | 0.62 | -0.35 | 0.71 (0.18-2.81) |
| | Over \$20000 | 31 (3.94) | 9 (3.78) | 0.93 | 0.06 | 1.06 (0.24-4.66) |
| | Under \$20000 | 17 (2.16) | 2 (0.84) | 0.4 | -0.84 | 0.43 (0.06-3.01) |
| | Missing | 27 (3.43) | 16 (6.73) | - | - | - |
| Diabetes duration | - | 9.05 (±11.05) | 16.33 (±12.57) | ≤ 0.0001 | 0.05 | 1.05 (1.04-1.07) |

Notes: This table only relates to those individuals who have been determined as having diabetes by our selection criteria: 1, Self-reported diabetes (DIQ010); 2, On anti-diabetes drugs (DIQ070); 3, Taking insulin (DIQ050); 4,

Fasting blood sugar (FBS) ≥ 6.1 (110mg/dl) (LBDGLUSI); 5, Random blood sugar (RBS) ≥ 11.1 (200mg/dl)

(LBDSGLSI); 6, Oral glucose tolerance test (OGTT) \geq 200mg/dl (LBDGLTSI); 7, Glycohemoglobin (HbA1c) \geq 6.5% (LBXGH). Ethnicity, education, and diabetes duration contain at least one term that is statistically significant. $^{\pm}$ includes 12th grade with no diploma

Table 2. Retinal lesions that constitute diabetic retinopathy outcome.

398

399

400401402403

404

405

| Retinal co-morbidity | n (%) | β-coefficient | OR (95% CI) | p-value | FDR-adjusted p-value |
|--|-------------|---------------|------------------------|----------|----------------------|
| Retinal microaneurysms only, worse eye | 129 (12.59) | 5.67 | 288.87 (127.66-653.68) | ≤ 0.0001 | ≤ 0.0001 |
| Retinal hard exudate, worse eye | 86 (8.39) | 3.72 | 41.34 (20.31-84.17) | ≤ 0.0001 | ≤ 0.0001 |
| Retinal blot hemorrhages, worse eye | 47 (4.59) | 3.36 | 28.71 (14.11-58.42) | ≤ 0.0001 | ≤ 0.0001 |
| Retinal soft exudate, worse eye | 76 (7.41) | 4.2 | 66.49 (26.44-167.21) | ≤ 0.0001 | ≤ 0.0001 |
| IRMA, worse eye | 62 (6.05) | 2.85 | 17.36 (9.06-33.26) | ≤ 0.0001 | ≤ 0.0001 |
| Macular edema, worse eye | 51 (4.98) | 3.88 | 48.24 (17.18-135.44) | ≤ 0.0001 | ≤ 0.0001 |
| Retinal fibrous proliferation, worse eye | 19 (1.85) | 3.41 | 30.19 (6.92-131.67) | ≤ 0.0001 | ≤ 0.0001 |
| Macular edema in center, worse eye | 26 (2.54) | 4.53 | 92.33 (12.45-684.9) | ≤ 0.0001 | ≤ 0.0001 |
| Retinal new vessels elsewhere, worse eye | 15 (1.46) | 3.12 | 22.68 (5.08-101.23) | ≤ 0.0001 | 0.0003 |

Notes: Lesions are taken from the NHANES *ophthalmology - retinal imaging* (OPXRET_E) dataset. Only lesions with FDR-adjusted p≤0.05 are listed. Soft exudate is now termed cotton wool spots.

Table 3. Laboratory variables associated with retinopathy in individuals with diabetes.

| | Unadju | sted / Non- | -covaria | te adjusted | Age-ad | justed | | | Ethnici | ity-adjusted | i | | Diabete | s duration- | adjuste | ed |
|--|-----------------------|-------------------------|-----------------|------------------------------|-----------------------|-------------------------|-----------------|------------------------------|-----------------------|-------------------------|-----------------|------------------------------|-----------------------|-------------------------|-----------------|------------------------------|
| Description | β- coeffi cient | OR (95% CI) | p- val ue | FDR- adjusted p- value | β- coeffi cient | OR (95% CI) | p- val ue | FDR- adjusted p- value | β- coeffi cient | OR (95% CI) | p- val ue | FDR- adjusted p- value | β- coeffi cient | OR (95% CI) | p- val ue | FDR- adjusted p- value |
| Glycohemoglobin (%) | 0.82 | 2.27 (1.84- 2.8) | 0.0 | 0.0003 | 0.85 | 2.34 (1.87- 2.92) | 0.0 | 0.0011 | 0.83 | 2.28 (1.82- 2.87) | 0.0 | 0.0036 | 0.72 | 2.05 (1.55- 2.73) | 0.0 002 | 0.0341 |
| Glucose, serum (mmol/L) | 0.54 | 1.72 (1.42- 2.08) | 0.0 001 | 0.0047 | 0.57 | 1.77 (1.45- 2.15) | 0.0 001 | 0.0115 | 0.54 | 1.71 (1.41- 2.09) | 0.0 002 | 0.0334 | 0.36 | 1.43 (1.1- 1.86) | 0.0 180 | 0.0520 |
| Osmolality (mmol/Kg) | 0.49 | 1.63 (1.34- 1.99) | 0.0 002 | 0.0143 | 0.45 | 1.57 (1.3- 1.9) | 0.0 004 | 0.0127 | 0.49 | 1.63 (1.34- 1.99) | 0.0 005 | 0.0707 | 0.39 | 1.48 (1.12- 1.94) | 0.0 140 | 0.0415 |
| Albumin, urine (mg/L) | 0.45 | 1.57 (1.28- 1.93) | 0.0 006 | 0.0288 | 0.43 | 1.53 (1.24- 1.88) | 0.0 012 | 0.0127 | 0.42 | 1.53 (1.25- 1.87) | 0.0 017 | 0.1418 | 0.25 | 1.28 (0.98- 1.68) | 0.0 905 | 0.1617 |
| Hemoglobin (g/dL) | -0.33 | 0.72 (0.61- 0.85) | 0.0 013 | 0.0387 | -0.30 | 0.74 (0.63- 0.88) | 0.0 042 | 0.0234 | -0.29 | 0.75 (0.62- 0.9) | 0.0 094 | 0.2638 | 0.00 | 1 (0.73- 1.37) | 0.9 784 | 0.9883 |
| Fasting Glucose (mmol/L) | 0.49 | 1.63 (1.28- 2.07) | 0.0 011 | 0.0387 | 0.51 | 1.66 (1.3- 2.13) | 0.0 013 | 0.0127 | 0.46 | 1.59 (1.25- 2.02) | 0.0 031 | 0.2290 | 0.22 | 1.24 (0.93- 1.66) | 0.1 687 | 0.2731 |
| 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanol (NNAL), urine (ng/mL) | -0.26 | 0.77 (0.67- 0.88) | 0.0 021 | 0.0539 | -0.20 | 0.82 (0.71- 0.94) | 0.0 133 | 0.0552 | -0.28 | 0.75 (0.65- 0.87) | 0.0 033 | 0.2290 | -0.25 | 0.78 (0.52- 1.19) | 0.2 655 | 0.4061 |
| Iodine, urine (ug/L) | -0.17 | 0.84 (0.76- 0.93) | 0.0 039 | 0.0873 | -0.21 | 0.81 (0.73- 0.9) | 0.0 022 | 0.0156 | -0.15 | 0.86 (0.77- 0.96) | 0.0 181 | 0.2638 | -0.29 | 0.75 (0.63- 0.89) | 0.0 054 | 0.0341 |
| Cobalt, urine (ug/L) | -0.51 | 0.6 (0.44- 0.82) | 0.0 052 | 0.1033 | -0.50 | 0.6 (0.45- 0.82) | 0.0 058 | 0.0300 | -0.51 | 0.6 (0.44- 0.81) | 0.0 073 | 0.2638 | -0.52 | 0.59 (0.45- 0.78) | 0.0 021 | 0.0341 |
| Hematocrit (%) | -0.31 | 0.73 (0.6- 0.89) | 0.0 061 | 0.1089 | -0.28 | 0.76 (0.62- 0.92) | 0.0 148 | 0.0595 | -0.28 | 0.75 (0.62- 0.92) | 0.0 202 | 0.2638 | -0.03 | 0.97 (0.7- 1.35) | 0.8 787 | 0.9329 |
| Blood urea nitrogen (mmol/L) | 0.33 | 1.4 (1.13- 1.73) | 0.0 075 | 0.1225 | 0.27 | 1.31 (1.01- 1.71) | 0.0 645 | 0.1584 | 0.35 | 1.43 (1.16- 1.75) | 0.0 066 | 0.2638 | 0.15 | 1.17 (0.87- 1.57) | 0.3 233 | 0.4793 |
| Albumin (g/L) | -0.22 | 0.8 (0.69- 0.93) | 0.0 116 | 0.1736 | -0.21 | 0.81 (0.69- 0.94) | 0.0 183 | 0.0687 | -0.19 | 0.83 (0.7- 0.99) | 0.0 575 | 0.3225 | -0.09 | 0.92 (0.74- 1.14) | 0.4 412 | 0.5899 |
| Urinary Triclosan (ng/mL) | -0.42 | 0.65 (0.49- 0.88) | 0.0 126 | 0.1743 | -0.40 | 0.67 (0.5- 0.89) | 0.0 165 | 0.0639 | -0.42 | 0.66 (0.49- 0.89) | 0.0 195 | 0.2638 | -0.60 | 0.55 (0.36- 0.83) | 0.0 135 | 0.0412 |
| Mean cell hemoglobin (pg) | -0.24 | 0.79 (0.66- | 0.0 159 | 0.2046 | -0.27 | 0.77 (0.65- | 0.0 076 | 0.0368 | -0.17 | 0.84 (0.7- | 0.1 069 | 0.4855 | -0.01 | 0.99 (0.76- | 0.9 174 | 0.9489 |

| | | 0.93) | | | | 0.91) | | | | 1.02) | | | | 1.28) | | |
|--|-------|-------------------------|------------|--------|-------|-------------------------|------------|--------|-------|-------------------------|------------|--------|-------|-------------------------|------------|--------|
| Lead, urine $(\mu g/L)$ | -0.40 | 0.67 (0.49- 0.91) | 0.0 222 | 0.2668 | -0.40 | 0.67 (0.49- 0.91) | 0.0 230 | 0.0831 | -0.41 | 0.66 (0.49- 0.9) | 0.0 228 | 0.2638 | -0.43 | 0.65 (0.43- 0.99) | 0.0 658 | 0.1312 |
| Creatinine, urine (µmol/L) | -0.22 | 0.8 (0.67- 0.97) | 0.0 348 | 0.2723 | -0.19 | 0.83 (0.68-1) | 0.0 710 | 0.1664 | -0.27 | 0.77 (0.64- 0.92) | 0.0 156 | 0.2638 | -0.28 | 0.76 (0.64- 0.9) | 0.0 070 | 0.0341 |
| Alanine aminotransferase (ALT) (U/L) | -0.25 | 0.78 (0.62- 0.97) | 0.0 380 | 0.2723 | -0.20 | 0.82 (0.66- 1.02) | 0.0 965 | 0.2003 | -0.22 | 0.81 (0.64- 1.01) | 0.0 869 | 0.4259 | -0.09 | 0.92 (0.68- 1.23) | 0.5 656 | 0.6993 |
| Creatinine (µ mol/L) | 0.24 | 1.27 (1.04- 1.54) | 0.0 335 | 0.2723 | 0.18 | 1.19 (0.96- 1.48) | 0.1 291 | 0.2529 | 0.20 | 1.23 (0.99- 1.53) | 0.0 933 | 0.4362 | 0.13 | 1.14 (0.89- 1.45) | 0.3 111 | 0.4699 |
| Red blood cell count (million cells/ μL) | -0.19 | 0.82 (0.7- 0.97) | 0.0 372 | 0.2723 | -0.13 | 0.88 (0.74- 1.04) | 0.1 439 | 0.2740 | -0.19 | 0.83 (0.7- 0.98) | 0.0 540 | 0.3172 | 0.01 | 1.01 (0.74- 1.37) | 0.9 623 | 0.9769 |
| Mean cell volume (fL) | -0.21 | 0.81 (0.68- 0.98) | 0.0 463 | 0.2723 | -0.25 | 0.78 (0.65- 0.93) | 0.0 159 | 0.0623 | -0.15 | 0.86 (0.71- 1.06) | 0.1 865 | 0.6799 | -0.05 | 0.95 (0.72- 1.26) | 0.7 361 | 0.8368 |
| Platelet count (1000 cells/µL) | -0.21 | 0.81 (0.68- 0.98) | 0.0 435 | 0.2723 | -0.18 | 0.83 (0.68- 1.02) | 0.1 005 | 0.2049 | -0.23 | 0.79 (0.67- 0.94) | 0.0 216 | 0.2638 | -0.29 | 0.75 (0.57- 0.99) | 0.0 616 | 0.1250 |
| Mean platelet volume (fL) | 0.24 | 1.27 (1.04- 1.55) | 0.0 352 | 0.2723 | 0.26 | 1.3 (1.06- 1.59) | 0.0 243 | 0.0835 | 0.22 | 1.25 (1.02- 1.53) | 0.0 564 | 0.3225 | 0.09 | 1.09 (0.83- 1.43) | 0.5 336 | 0.6642 |
| Cotinine (ng/mL) | -0.15 | 0.86 (0.76- 0.99) | 0.0 451 | 0.2723 | -0.09 | 0.91 (0.79- 1.04) | 0.1 994 | 0.3443 | -0.18 | 0.84 (0.74- 0.95) | 0.0 221 | 0.2638 | -0.06 | 0.94 (0.66- 1.34) | 0.7 352 | 0.8368 |
| Insulin (pmol/L) | -0.32 | 0.73 (0.55- 0.97) | 0.0 469 | 0.2723 | -0.30 | 0.74 (0.55-1) | 0.0 699 | 0.1660 | -0.29 | 0.75 (0.56-1) | 0.0 734 | 0.3816 | -0.22 | 0.8 (0.51- 1.26) | 0.3 520 | 0.5062 |
| Blood cadmium (nmol/L) | -0.23 | 0.8 (0.65- 0.97) | 0.0 429 | 0.2723 | -0.25 | 0.78 (0.64- 0.95) | 0.0 273 | 0.0866 | -0.23 | 0.79 (0.64- 0.98) | 0.0 589 | 0.3225 | -0.28 | 0.76 (0.5- 1.16) | 0.2 224 | 0.3528 |
| Urinary perchlorate (ng/mL) | -0.25 | 0.78 (0.63- 0.95) | 0.0 294 | 0.2723 | -0.24 | 0.78 (0.63- 0.98) | 0.0 495 | 0.1267 | -0.24 | 0.78 (0.64- 0.96) | 0.0 399 | 0.2668 | -0.31 | 0.73 (0.53- 1.01) | 0.0 818 | 0.1525 |
| Urinary nitrate (ng/mL) | -0.28 | 0.75 (0.6- 0.94) | 0.0 264 | 0.2723 | -0.23 | 0.79 (0.63-1) | 0.0 675 | 0.1632 | -0.27 | 0.76 (0.6- 0.96) | 0.0 422 | 0.2688 | -0.34 | 0.71 (0.55- 0.91) | 0.0 186 | 0.0528 |
| Cesium, urine (µg/L) | -0.33 | 0.72 (0.54- 0.95) | 0.0 339 | 0.2723 | -0.32 | 0.72 (0.55- 0.96) | 0.0 390 | 0.1059 | -0.33 | 0.72 (0.54- 0.95) | 0.0 389 | 0.2665 | -0.34 | 0.71 (0.47- 1.06) | 0.1 161 | 0.1950 |
| Thallium, urine (μg/L) | -0.40 | 0.67 (0.48- 0.95) | 0.0 417 | 0.2723 | -0.39 | 0.68 (0.48- 0.96) | 0.0 488 | 0.1266 | -0.42 | 0.66 (0.47- 0.92) | 0.0 307 | 0.2638 | -0.48 | 0.62 (0.4- 0.94) | 0.0 414 | 0.0923 |
| 25OHD2+25OHD3 (nmol/L) | -0.24 | 0.79 | 0.0 | 0.2723 | -0.25 | 0.78 | 0.0 | 0.0831 | -0.18 | 0.83 | 0.1 | 0.5685 | -0.20 | 0.82 | 0.2 | 0.3401 |

| | | (0.65- | 279 | | | (0.65- | 230 | | | (0.66- | 390 | | | (0.61- | 129 | |
|------------------------------------|-------|--------|-----|--------|-------|--------|-----|--------|-------|----------|-----|--------|-------|--------|-----|--------|
| | | 0.95) | | | | 0.94) | | | | 1.04) | | | | 1.1) | | |
| Blood Toluene (ng/mL) | -0.21 | 0.81 | 0.0 | 0.2723 | -0.20 | 0.82 | 0.0 | 0.1029 | -0.22 | 0.8 | 0.0 | 0.3225 | -0.30 | 0.74 | 0.2 | 0.3896 |
| | | (0.68- | 304 | | | (0.69- | 366 | | | (0.65- | 578 | | | (0.45- | 536 | |
| | | 0.96) | | | | 0.97) | | | | 0.98) | | | | 1.21) | | |
| C-reactive protein (mg/dL) | -0.19 | 0.82 | 0.0 | 0.3102 | -0.18 | 0.83 | 0.0 | 0.1820 | -0.25 | 0.78 | 0.0 | 0.2638 | -0.27 | 0.77 | 0.0 | 0.1063 |
| | | (0.69- | 551 | | | (0.69- | 827 | | | (0.66- | 153 | | | (0.6- | 489 | |
| | | 0.99) | | | | 1.01) | | | | 0.92) | | | | 0.98) | | |
| Barium, urine (µg/L) | -0.39 | 0.68 | 0.0 | 0.3114 | -0.38 | 0.69 | 0.0 | 0.1525 | -0.38 | 0.68 | 0.0 | 0.3885 | -0.44 | 0.64 | 0.0 | 0.0415 |
| | | (0.47- | 600 | | | (0.48- | 607 | | | (0.47-1) | 756 | | | (0.47- | 140 | |
| | | 0.99) | | | | 0.99) | | | | | | | | 0.87) | | |
| Urinary 4-tert-octylphenol (ng/mL) | -0.34 | 0.71 | 0.1 | 0.5259 | -0.33 | 0.72 | 0.1 | 0.3007 | -0.42 | 0.66 | 0.0 | 0.4203 | -0.82 | 0.44 | 0.0 | 0.0794 |
| | | (0.45- | 607 | | | (0.46- | 682 | | | (0.43- | 846 | | | (0.23- | 331 | |
| | | 1.12) | | | | 1.12) | | | | 1.01) | | | | 0.87) | | |
| Dimethyldithiophosphate (µg/L) | -0.31 | 0.74 | 0.1 | 0.4800 | -0.35 | 0.71 | 0.0 | 0.1782 | -0.21 | 0.81 | 0.2 | 0.7382 | -0.67 | 0.51 | 0.0 | 0.0887 |
| | | (0.51- | 173 | | | (0.49- | 783 | | | (0.59- | 319 | | | (0.29- | 388 | |
| | | 1.06) | | | | 1.01) | | | | 1.12) | | | | 0.91) | | |

Variables were first tested in an unadjusted / non-covariate adjusted analysis, and then again adjusting for age, ethnicity, and diabetes duration. To provide a broad overview, any variable passing nominal (i.e. prior to FDR-correction) p≤0.05 from either the non-covariate adjusted or any of the covariate-adjusted analyses are listed.

Table 4. RandomForestTM-selected variables (features).

| Marker | Group | Mean decrease accuracy | Mean decrease Gini | | |
|--|-----------------|------------------------|--------------------|--|--|
| Glycohemoglobin (%) | Diabetes status | 31.93719324 | 21.75225602 | | |
| C-reactive protein (mg/dL) | Immune markers | 11.51047187 | 10.1975135 | | |
| Potassium (mmol/L) | Renal function | 11.44142126 | 8.198116194 | | |
| Albumin, urine (mg/L) | Renal function | 8.220187056 | 10.21346621 | | |
| Monocyte number (1000 cells/uL) | Immune markers | 7.663589246 | 3.957711466 | | |
| Osmolality (mmol/Kg) | Renal function | 7.510989556 | 5.33445026 | | |
| White blood cell count (1000 cells/uL) | Immune markers | 7.440157644 | 4.405168072 | | |
| Blood urea nitrogen (mmol/L) | Renal function | 7.224789174 | 5.073947519 | | |
| Segmented neutrophils num (1000 cell/uL) | Immune markers | 7.020397225 | 4.067402271 | | |
| Fasting Glucose (mmol/L) | Diabetes status | 6.563694988 | 2.826827797 | | |
| Red cell distribution width (%) | Hematocrit | 6.138538515 | 4.947185792 | | |
| Urinary nitrate (ng/mL) | Renal function | 5.899174386 | 5.844258103 | | |
| Glucose, serum (mmol/L) | Diabetes status | 5.85339684 | 4.77357191 | | |
| 2-hydroxyphenanthrene (ng/L) | Toxins / Metals | 4.028082549 | 2.307374348 | | |
| MCHC (g/dL) | Hematocrit | 3.936015913 | 3.896804592 | | |
| Creatinine (µmol/L) | Renal function | 3.530916132 | 3.747500758 | | |
| Mono-2-ethyl-5-carboxypentyl phthalate | Toxins / Metals | 2.996581682 | 2.212151134 | | |
| Blood Nitromethane (pg/mL) | Toxins / Metals | 2.936160917 | 3.31634662 | | |
| Phosphorus (mmol/L) | Toxins / Metals | 2.819084205 | 3.768671211 | | |
| Total Cholesterol (mmol/L) | Sterols | 2.448578413 | 3.833301666 | | |
| Enterodiol (ng/mL) | Sterols | 2.401651721 | 2.722762228 | | |
| Hematocrit (%) | Hematocrit | 2.364741874 | 4.841281382 | | |
| Mono-n-octyl phthalate (ng/mL) | Toxins / Metals | 2.215508752 | 0.231647322 | | |
| Mean cell hemoglobin (pg) | Hematocrit | 2.183482824 | 4.292282119 | | |
| Gamma glutamyl transferase (U/L) | Liver Function | 1.989695745 | 4.015070221 | | |
| Systolic blood pressure | Blood pressure | 1.892815461 | 8.85430752 | | |
| Blood o-Xylene (ng/mL) | Toxins / Metals | 1.670964308 | 3.708248225 | | |
| Lactate dehydrogenase LDH (U/L) | Liver Function | 1.593869272 | 4.231659273 | | |
| 9-hydroxyfluorene (ng/L) | Toxins / Metals | 1.430814333 | 2.206778568 | | |
| Cholesterol (mmol/L) | Sterols | 1.201366974 | 4.025207689 | | |
| 3-hydroxyphenanthrene (ng/L) | Toxins / Metals | 1.00569817 | 1.63630888 | | |

Notes: The model was initially trained on all laboratory variables in an unsupervised fashion, with Kappa-based model tuning to select the optimum values for 'mtry' (the ideal number of variables to randomly sample) and 'ntrees' (the ideal number of trees). Only variables contributing >1% mean decrease in accuracy from the initial model were retained, followed by recursive steps to remove low-informative variables. Variables are manually assigned to groups based on similar organ function or other characteristic. The Gini importance measure relates to the 'splitting' criterion that is employed in classification trees, and it is known to be less biased for continuous variables (26), which naturally have more splitting points compared to categorical variables. 'Group' is manually curated.

Table 5. Final clinical risk models.

| Model | Wald test p-value | McFadden R ² | Nagelkerke R ² | AUC (95% CI) |
|-------------------------------|-------------------|-------------------------|---------------------------|---------------------|
| Diabetes Status | ≤ 0.0001 | 0.102 | 0.142 | 0.72 (0.677-0.763) |
| Hematocrit | 0.0023 | 0.007 | 0.009 | 0.57 (0.539-0.601) |
| Blood Pressure (BP) | ≤ 0.0001 | 0.017 | 0.024 | 0.586 (0.554-0.618) |
| Immune Markers | 0.42 | 0.002 | 0.002 | 0.527 (0.495-0.559) |
| Renal function tests (renal) | ≤ 0.0001 | 0.039 | 0.054 | 0.636 (0.604-0.669) |
| Sterols (include cholesterol) | 0.055 | 0.012 | 0.017 | 0.582 (0.522-0.642) |

| Toxins / Metals | 0.94 | 0.029 | 0.041 | 0.589 (0.478-0.7) |
|-----------------------------------|----------|-------|-------|---------------------|
| Liver function tests | 0.07 | 0.002 | 0.003 | 0.525 (0.494-0.557) |
| Diabetes control + BP + Renal | ≤ 0.0001 | 0.13 | 0.18 | 0.73 (0.686-0.774) |
| function | | | | |
| Diabetes control + BP + renal | ≤ 0.0001 | 0.135 | 0.184 | 0.737 (0.694-0.78) |
| function + Hematocrit | | | | |
| Diabetes control + BP + renal | ≤ 0.0001 | 0.238 | 0.315 | 0.823 (0.765-0.881) |
| function + Hematocrit + Sterols + | | | | |
| Liver function | | | | |
| All groups ± | 0.00013 | 0.272 | 0.355 | 0.84 (0.783-0.897) |

Features from RandomForestTM were grouped logically based on similar function or clinical use (**Table 4**) and then tested independently in a univariate or multivariate regression model against DR outcome.

 \pm The only toxins / metal included was Phosphorus (mmol/L) – others filtered out due to high missingness (>50%), resulting in difficulty fitting model.

FIGURE LEGENDS

Figure 1. Cohort selection process for NHANES 2007-8.

Figure 2.

Penalized regression-selected variables.

Variables were selected from a 100x cross-validated model with α =0.5. Final variable selection was based on coefficients not shrunk to 0. Model accuracy was determined to be 78.4% accuracy and AUC 0.71 (95% CI: 0.65-0.77).

Figure 3. Final clinical risk models.


Features from RandomForest™ were grouped logically based on similar function or clinical use (**Table 4**) and then tested independently in a univariate or multivariate regression model against DR outcome. A final risk model including markers of hypertension, hypercholesterolemia, renal and liver function tests, and hematocrit achieved AUC 0.84 (0.78-0.9).

REFERENCES

- 1. Feman SS. The natural history of the first clinically visible features of diabetic retinopathy. Trans Am Ophthalmol Soc. 1994;92:745-73.
- 2. Chao JR, Lai M-Y, Azen SP, Klein R, Varma R, Group tLALES. Retinopathy in Persons without Diabetes: The Los Angeles Latino Eye Study. Investigative Ophthalmology & Visual Science. 2007;48(9):4019-25.
- 3. Venkatramani J, Mitchell P. Ocular and systemic causes of retinopathy in patients without diabetes mellitus. BMJ (Clinical research ed). 2004;328(7440):625-9.
- 4. Singh R, Ramasamy K, Abraham C, Gupta V, Gupta A. Diabetic retinopathy: an update. Indian J Ophthalmol. 2008;56(3):178-88.
- 5. Wang W, Lo ACY. Diabetic Retinopathy: Pathophysiology and Treatments. Int J Mol Sci. 2018;19(6):1816.

- 6. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556-64.
- 7. Heintz E, Wiréhn AB, Peebo BB, Rosenqvist U, Levin LA. Prevalence and healthcare costs of diabetic retinopathy: a population-based register study in Sweden. Diabetologia. 2010;53(10):2147-54.
- 8. Group UPDSU. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837-53.
- 9. Chatziralli IP. The Role of Dyslipidemia Control in the Progression of Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus. Diabetes Ther. 2017;8(2):209-12.
- 10. Liu L, Quang ND, Banu R, Kumar H, Tham Y-C, Cheng C-Y, et al. Hypertension, blood pressure control and diabetic retinopathy in a large population-based study. PLoS One. 2020;15(3):e0229665-e.
- 11. Chen X, Meng Y, Li J, She H, Zhao L, Zhang J, et al. Serum uric acid concentration is associated with hypertensive retinopathy in hypertensive chinese adults. BMC Ophthalmol. 2017;17(1):83-.
- 12. Luo B-A, Gao F, Qin L-L. The Association between Vitamin D Deficiency and Diabetic Retinopathy in Type 2 Diabetes: A Meta-Analysis of Observational Studies. Nutrients. 2017;9(3):307.
- 13. Kong X, Wang J, Gao G, Tan M, Ding B, Li H, et al. Association between Free Thyroxine Levels and Diabetic Retinopathy in Euthyroid Patients with Type 2 Diabetes Mellitus. Endocr Res. 2020;45(2):111-8.
- 14. Merin S, Freund M. Retinopathy in severe anemia. Am J Ophthalmol. 1968;66(6):1102-6.
- 15. Khan AA, Rahmani AH, Aldebasi YH. Diabetic Retinopathy: Recent Updates on Different Biomarkers and Some Therapeutic Agents. Curr Diabetes Rev. 2018;14(6):523-33.
- 16. Moriya T, Tanaka S, Kawasaki R, Ohashi Y, Akanuma Y, Yamada N, et al. Diabetic retinopathy and microalbuminuria can predict macroalbuminuria and renal function decline in Japanese type 2 diabetic patients: Japan Diabetes Complications Study. Diabetes Care. 2013;36(9):2803-9.
- 17. Chen YH, Chen HS, Tarng DC. More impact of microalbuminuria on retinopathy than moderately reduced GFR among type 2 diabetic patients. Diabetes Care. 2012;35(4):803-8.
- 18. Lim LS, Tai ES, Mitchell P, Wang JJ, Tay WT, Lamoureux E, et al. C-reactive Protein, Body Mass Index, and Diabetic Retinopathy. Investigative Ophthalmology & Visual Science. 2010;51(9):4458-63.
- 19. Raymond NT, Varadhan L, Reynold DR, Bush K, Sankaranarayanan S, Bellary S, et al. Higher prevalence of retinopathy in diabetic patients of South Asian ethnicity compared with white Europeans in the community: a cross-sectional study. Diabetes care. 2009;32(3):410-5.
- 20. Spanakis EK, Golden SH. Race/ethnic difference in diabetes and diabetic complications. Current diabetes reports. 2013;13(6):814-23.
- 21. Wong TY, Klein R, Islam FMA, Cotch MF, Folsom AR, Klein BEK, et al. Diabetic retinopathy in a multi-ethnic cohort in the United States. American journal of ophthalmology. 2006;141(3):446-55.

- 22. McGinnis DP, Brownstein JS, Patel CJ. Environment-Wide Association Study of Blood Pressure in the National Health and Nutrition Examination Survey (1999–2012). Scientific Reports. 2016;6(1):30373.
- 23. Zhuang X, Guo Y, Ni A, Yang D, Liao L, Zhang S, et al. Toward a panoramic perspective of the association between environmental factors and cardiovascular disease: An environment-wide association study from National Health and Nutrition Examination Survey 1999-2014. Environ Int. 2018;118:146-53.
- 24. Hall MA, Dudek SM, Goodloe R, Crawford DC, Pendergrass SA, Peissig P, et al. Environment-wide association study (EWAS) for type 2 diabetes in the Marshfield Personalized Medicine Research Project Biobank. Pac Symp Biocomput. 2014:200-11.
- 25. Patel CJ, Rehkopf DH, Leppert JT, Bortz WM, Cullen MR, Chertow GM, et al. Systematic evaluation of environmental and behavioural factors associated with all-cause mortality in the United States national health and nutrition examination survey. Int J Epidemiol. 2013;42(6):1795-810.
- 26. Nembrini S, König IR, Wright MN. The revival of the Gini importance? Bioinformatics. 2018;34(21):3711-8.
- 27. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society Series B (Methodological). 1995;57(1):289-300.
- 28. Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia. 2001;44(2):156-63.
- 29. Klein R, Klein BEK. Blood pressure control and diabetic retinopathy. Br J Ophthalmol. 2002;86(4):365-7.
- 30. Zheng Y, Lamoureux EL, Lavanya R, Wu R, Ikram MK, Wang JJ, et al. Prevalence and risk factors of diabetic retinopathy in migrant Indians in an urbanized society in Asia: the Singapore Indian eye study. Ophthalmology. 2012;119(10):2119-24.



Footnotes:

¹ Laboratory datasets (2007-8): ALB_CR_E; APOB_E; BIOPRO_E; BPX_E; CARB_E; CBC_E; COTNAL_E; CRP_E; DEET_E; ENX_E; EPH_E; FASTQX_E; FERTIN_E; FOLATE_E; FOLFMS_E; GHB_E; GLU_E; HDL_E; HEPA_E; HEPB_S_E; HEPC_E; HIV_E; HPVSER_E; HPVSWR_E; HSV_E; IHG_E; OGTT_E; OPD_E; PAH_E; PBCD_E; PERNT_E; PFC_E; PHTHTE_E; PHYTO_E; POOLTF_E; PP_E; PSA_E; SSHCV_E; SSUSG_E; TCHOL_E; TFR_E; THYROD_E; TRIGLY_E; UAM_E; UCPREG_E; UHG_E; UHG_E; UHOPM_E; UPP_E; VID_E; VIT_B6_E; VOC_E; VOCMWB_E; VOCWB_E.



